Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Change in Cash (2020 - 2025)

Historic Change in Cash for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to $16.1 million.

  • Tarsus Pharmaceuticals' Change in Cash rose 42908.9% to $16.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$60.9 million, marking a year-over-year decrease of 2073.05%. This contributed to the annual value of -$127.6 million for FY2024, which is 18322.04% down from last year.
  • According to the latest figures from Q3 2025, Tarsus Pharmaceuticals' Change in Cash is $16.1 million, which was up 42908.9% from -$79.1 million recorded in Q2 2025.
  • Tarsus Pharmaceuticals' Change in Cash's 5-year high stood at $119.9 million during Q3 2023, with a 5-year trough of -$97.8 million in Q4 2022.
  • In the last 5 years, Tarsus Pharmaceuticals' Change in Cash had a median value of -$4.9 million in 2024 and averaged -$2.8 million.
  • As far as peak fluctuations go, Tarsus Pharmaceuticals' Change in Cash surged by 84459.75% in 2021, and later crashed by 446979.71% in 2024.
  • Over the past 5 years, Tarsus Pharmaceuticals' Change in Cash (Quarter) stood at -$12.5 million in 2021, then tumbled by 684.58% to -$97.8 million in 2022, then skyrocketed by 98.24% to -$1.7 million in 2023, then tumbled by 4469.8% to -$78.8 million in 2024, then surged by 120.39% to $16.1 million in 2025.
  • Its Change in Cash stands at $16.1 million for Q3 2025, versus -$79.1 million for Q2 2025 and $81.0 million for Q1 2025.